A cetaminophen is a widelyused anal-KE Y WORDS: acetaminophen, acetaminophen toxicity, asthma, pharmacoepidemiology.
gesic and antipyretic drug in the US, with annual sales of approximately $1 billion.' Although it is considered relativelysafe, concernsare being expressed over excessive acetaminophen consumption. The organs principally affected by acetaminophen overdose are the liverand kidneys, butdose-dependent lungtoxicity may also occur.' Instances of acute lung injury in patients with acetaminophen-induced fulminant hepatic failure have been reported.' Advanced liverdisease is associated with hypoxemia and respiratory failure by various mechanisms,' suggesting that the lung injury may be a result of physiologic changes related to hepatic dysfunction rather than the direct effect of acetaminophen. Although the cause of lung injury among acetaminophen-induced fulminant liver failure cases is not clear, possible reasons are excessive production or lack of clearance of an endogenous vasodilator associated with acute liver failure, increased intracranial pressure, or a direct cytotoxic effect of acetaminophen metabolites on the lung.' It has also been suggested that acetaminophen-induced glutathione deple-Author information providedat end of text. BACKGROUND: Studies have examined the association between acetaminophen use and asthma; however. their interpretation is limited by several methodologic issues. OBJECTIVE: To investigate the association between recent and chronic prescription-acquired acetaminophen use and asthma.
METHODS: This retrospective case-control studyused a 10% random sample of the IMS LifeLink commercial claimsdata from 1997to 2009. Caseshad to have at least 1 incidentclaim of asthma; 3:1 controls matched on age, sex, and region were randomlychosen. Acotaminophen exposure, dose, and duration were measured in the 7-and 30-day(recent) and the l-year (chronic) look-back periods. Multivariable conditionallogistic regression was used to estimatethe risk of asthmaassociated with acetaminophen use adjusted for comorbidities, other drugs increasing asthma risk, and heal th system factors. RESULTS : Thero were 28,892 cases and 86,676 controls, with mean age of 42.8 years: 37.7% were males, and 22.6% of cases and 18.2% of controls had acetaminophen exposurein the pre-indexyear, with mean cumulative doses of 78.7 g and 59.8 g, respectively. There was no significant association between recent prescription acetaminophen exposure and asthma(7 days: OR 1.02, P = 0.74: 30 days: OR 0.97, P = 0.38). Cumulative prescription acetaminophen dose in the year prior increased asthma risk compared to acetaminophen nonusers (s:1 kg: OR 1.09, P < 0.001 and>1 kg: OR = 1.60, P = 0. (2) . Durat ion of prescription acetaminophen use greater than 30 days was associated with elevated asthma risk (OR 1.39, P < 0.(01). CONCLUSIONS: Chronic prescription-acquired acetaminophen use was associated with an increased riskof asthma, whilerecent use was not.However, over-the-counter acetaminophen use was not captured in this study and further epidemiologic research with completeacetaminophen exposureascertainment and research on pathophysiologic mechanisms is needed to confirm Iheserelat ionships.
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STUDY DESIGN ANDDATA SOURCE
Eligible cases wereindividuals aged 18years or olderwith at least1 incident primary diagnosis of asthma (493.xx)20 be-tweenJanuary 1, 1998,andDecember 31, 2009 . The dateof an incident asthma diagnosis was designated as the index dateand thecaseswererequired to havecontinuous planenrollment in the pre-index year. Sincethis study was partof a largerprojectwith 3 outcomes, to keep the methods consistent,caseswithdiagnoses of hepatotoxicity, renaldisease, or asthmain the pre-index year were excluded. The exclusion codes contained a broader setof related conditions in addition to the case definitions (Supplementary Material, Tables S1-S4, www.hwbooks.com/pdf/appendicesIR430.pdf) to exclude persons withpossible manifestations of thedisease. We alsoexcluded cases withprevious liver, kidney, or lungtransplant; those receiving immunosuppressant therapy; andthose withliver, renal,respiratory tractcancer, or secondary malignancies.
This study was part of a largerprojectexamining the association between recent andchronic acetaminophen use and hepatic (hepatotoxicity) and nonhepatic (renal diseaseand asthma) outcomes using a retrospective case-control design," The data source usedwasa 10%random sample of the IMS LifeLink Health Plans'commercial claims datafrom 1997 to 2009.This dataset consists of claims fromover 98 managed careorganizations in theUS andis representative of thecommercially insured population in the US with respectto age, sex,andregion. The datainclude pharmacy claims, inpatient andoutpatient claims, andenrollment information for about 6 million individuals. The data containrecords for both OTC andprescription acetaminophen-containing products billed as a prescription claim.The acetaminophen records from this datasource havebeen usedin our previous study examining thetrends in acetaminophen useandpotential overuse," asedby knowledge about the studyoutcome," Given these advantages and a lackof claims-based studies examining the acetaminophen-asthma link,we sought to investigate the association betweenrecentand chronic prescription-acquired acetaminophen consumption and asthma using a large nationally representative commercial claims database. tion, independentof advanced liver disease, leads to lung damage, and regular acetaminophen users without liver manifestations may be at an increased risk of asthma.' A review of publications on this topic' reported an association between acetaminophen use and the developmentof asthma symptoms, but mechanistic studies in humans to support these associations have not been performed. Alterations in lung glutathione levels" and/or metabolic activation of acetaminophen,' or cyclooxygenase-mediated effects 2 may represent important mechanismsin the pathogenesis of asthmabasedon data from experimental animal models.
The hypothesis of an association between acetaminophen use and asthma was first proposed about a decade ago," At the population level, associations between per capita acetaminophen consumption and the prevalence of asthma have been reported," The prevalence of asthma in the US has increased over the last 30 years for reasons not completely understood.' Because of a surge in asthma prevalence that occurredconcurrently with increasing acetaminophen use, there is renewed interest in the role of acetaminophen in the development of asthma/" Several reviews on thistopic suggested a positive linkbetween acetaminophen use and the risk of asthma in adults andchild.ren,9.11 butwhether thisassociation iscausal remains debatable, 12 The interpretation of epidemiologic studies 7 ,13.1s supporting the acetaminophen-asthma association in adults is limited by a numberof issues,suchas lack of rigorous case deftnitions and not controlling for key confounders? Moreover, these studies have measured acetaminophen use in terms of frequency of userather thanthedose,which plays a major rolein determining thedegree of glutathione depletion. Finally, only 1 study" used incident casesratherthanprevalent asthmacases,and there is no way of knowing whether acetaminophen use precededasthmaor vice versa in these other studies.To our knowledge, there are no large-scale claims-based studies examining the association between acetaminophen use andasthma. Oneof thereasons couldbe incomplete acetaminophen exposure ascertainment because of incomplete recording of over-the-counter (OTC) acetaminophen use. Chronic prescription-acquired acetaminophen use has increased in the past few years,which parallels increases in theuseof acetaminophen/opioid combinationproducts.w-? Our previous claims-based studyof annual acetaminophen use reported approximately 30%of acetaminophen userswithpotential peakacetaminophen consumption morethanthe maximum recommended daily dose (4 glday) basedexclusively on prescription claims, indicating that administrative claims data capture high-risk acetaminophen use." Unlike retrospective interview-based Three controls for every case matchedon age, sex, and studies, claims-based studies arenotbiased dueto differential geographic location wererandomly selected from a group of exposure recallof the casescompared to the controls. Phar-individuals without evidence of asthma, hepatotoxicity, and macyclaimsrecordthe startand end datesof a prescription nephrotoxicity at the end of the follow-up period. Controls and the amountof drug prescribed and therefore are not bi-wereassigned the sameindex dateas thecorresponding case theannals.com The Annals ofPharmacotherapy • 2012 December, Volume 46 • 1599 and wererequired to havecontinuous planenrollment in the pre-index year. Weexcluded controls thathad a previous diagnosis codeof acetaminophen poisoning (965Ax) . 21 Other exclusion criteria werethe sameas those of the cases. Selectionof cases andcontrols is depicted in Figure I .
ACETAMINOPHEN EXPOSURE MEASURES
contained in all prescriptions in the 30 days pre-index,dividedby the totaldaysof acetaminophen use. 3. Cumulative dose in the pre-index year: the sum of acetaminophen doses from all acetaminophen-containing prescriptions during the pre-index year. Table I describes the details of all of the acetaminophen use measures.
Acetaminophen-containing products were identified using uniquegeneric productidentifier codes in the data. We measured any acetaminophen exposure, doses,and use durations for recent (7 and 30 days pre-index) and chronic (365 days pre-index)look-backperiods.Doses calculated were as follows:
I. Potential maximum daily dose (PMDD) in the 7 and 30 days pre-index: the highest potential acetaminophen dose calculated in the pre-indexperiod using the days supplied, strength, and quantity fields in the data. Overlapping prescriptions were identified usingfill datesand days supplied, and the daily doses weresummedto obtain the potential maximum dose. 2. Potential averagedaily dose in the pre-indexmonth:
dose obtained by summing the acetaminophen doses
OTHER COVARIATES
We obtained data on the following potential confounders in the pre-index period:
I. Medical conditions: These were measured in the 365day pre-index periodfor both recentand chronic analyses and included eczema," rhinitis,23,24 chronic obstructivepulmonarydisease.v acute respiratory tract infections.P'" gastrointestinal reflux disease,27,28 and cancer" (Table S5) measured. We also controlledfor use of single-ingredient unmixedopioid analgesics,since their use is linked to respiratory depression." 3. Health system variables: Using the enrollment information, we obtained data on insurance payer/plan type (Table 2) for our sample. In addition to the abovecovariates, we included a binary term for acetaminophen use in the 30 days pre-index to control for recentuse of acetaminophen for the chronic acetaminophen use models. We could not adjust for race sinceit was not available in our data source.
ANALYSIS
We obtained the baseline descriptive characteristics of our sample in the recent and chronicpre-indexperiods. X 2 Tests were used to conductbivariate comparisons between the characteristics of cases and controls. Adjustedand un-Prescription-Acquired Acetaminophen Useand the Risk ofAsthma in Adults adjusted conditional logistic regression models were used to determine the effect of recent and chronic acetaminophen use on the risk of asthma. Odds ratios and 95% confidence interval estimates obtained from the regression are reported. Dose-response relationships were assessed using the Cochran-Armitage trend test. All analyses were carried out using SAS version 9.2 (SAS Institute). This study was approved by the institutional review board of the University of Arkansas for MedicalSciences.
Results
Included in the study were 28,892incidentasthmacases and 86,676 controls ( Figure 1 ). The mean age of the sample was 42.8 years and 37.7% were males. Use of drugs and presence of comorbidities that increase asthma risk were significantly higher among the cases comparedto the controls (Table2). A total of 1415 cases (4.9%) and 3271 Acetaminophen Use of an acetaminophen-containing prescription for at least 1 day Yes/no No acetaminophen exposure exposure in the 7-day in the 7-day pre-index period in the 7-day pre-index period pre-index period PMDD In the 7-day
The highest potential acetaminophen dose on any day during the 7 PMDD =:4 g/day No acetaminophen use pre-index period days pre-index PMDD >4 g/day (PMDD = 0 g/day) Calculated using the days supplied, strength . and quan tity fields in the data Overlapping prescriptions were identified using fill dates and days supplied. and the daily doses were summed to obtain the PMDD Recent acet am inophen exposure mea sures (meas ur ed In the 30 days pre-Ind ex)
Acetaminophen
Use of an acetaminophen-containing prescription lor at least 1 day Yes/no No acetaminophen exposure exposura in the 30-in the 30-day pre-index period in the 30-day pre-index day pre-ind ex period period PMDD in the 30-d ay
The highest potential acetaminophen dose on any day during the 30 PMDD s4 g/day No acetaminophen use pre-index days pre-Index PMDD >4 g/day (PMDD = 0 g/day) Calculated using the days supplied, strength, and quantity fields in the data Overlapp ing prescriptions were identified using fill dates and days supplied. and the daily doses were summed to obtain the PMDD PADD in the pre-Dose obtained by summing the acetaminophen doses con tained in PADD s4 g/day
No acetaminophen use index month all prescriptions in the 30 days pre-index and dividing by the total PADD >4 g/day (PADD = 0 g/day) days of acetaminophe n use in the 30-day pre-index period 
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The Annals ofPharmacotherapy • 2012December, Volume 46 • 1601 controls (3.8%) were exposed to acetaminophen for at least 1 day in the 30 days pre-index, with mean maximum daily doses of 33935 mg and 3346.4 mg, respectively (Table 3 ).
In the pre-index year, 6537 cases (22.6%) and 15,809 controls (18.2%) had acetaminophen exposure, with mean cumulative doses of 78.7 g and 59 .8 g, respectively. The mean number of total days of acetaminophen use was significantly greater among the cases (32.2 days) compared to the controls (24.7 days) . More than 90% of the prescriptions used by both cases and controls were for opioid/acetaminophen combinations (Table 3) .
There was no significant association between any of the adjusted recent acetaminophen exposure measures and asthma (Table 4 ). To determine whether our study was sufficiently powered to detect significant differences between cases and controls, we performed power analysis using the Epicalc package in R software ." Assuming a true odds ra-tio of 1.5, the power of our study was >80% to detect significant differences with all of the recent acetaminophen variables (data not shown) .
Cumulative acetaminophen dose in the pre-index year increased the risk of asthma by 10-60% compared to acetaminophen nonusers (sl kg: OR 1.09,95% CI 1.05 to 1.13 and>1 kg: OR 1.60,95% CI 1.09 to 2.37, respectively; Table 5 ). Doses greater than 1 kg conferred a significantly higher risk compared to lower cumulative doses (p for trend =0.05). The risk of asthma with acetaminophen use 30 days or less in the pre-index year was 1.07 times that of nonusers and increased 1.39-fold when acetaminophen use duration was greater than 30 days (OR 1.07,95% CI 1.03 to 1.11 and OR 1.39,95% CI 1.27 to 1.53, respectively; p < 0.001 for trend; Table 5 ). Categories of PMDD and total acetaminophen use duration in the preindex year indicate that irrespective of the dose, the risk of asthma with acetaminophen use for 30 days or less was significantly lower than the risk conferred by durations longerthan 30 days (Table 5 ).
Discussion
In oursample, recent prescription-acquired acetaminophen use did not increase the risk of asthma. This is in agreement withstudies reporting no significant asthma risk with infrequent (less than monthly) acetaminophen use or use for up Prescription-AcquiredAcetaminophen Use and the Risk of Asthma in Adults to 22 days in 1 month,13·14 Although there are no studies reporting an association between recent acetaminophen use and asthma, acute acetaminophen overdose may have a direct cytotoxic effect on pneumocytesand lead to lung injury,' Whetheror not this lung injury leads to the development of asthmarequires further investigation. Chronic prescription-acquired acetaminophen use, however, increased the risk of asthma by 10-60% compared to acetaminophen nonuse. This is consistent with a recent meta-analysis that reported a 74% increased asthma risk (pooled OR 1.74) among adult acetaminophen users compared to nonusers." The risk conferred by cumulative dose in the pre-index year increased in a dose -dependent fashion. This is in keeping with the theory that acetaminophen-induced glutathione depletion in the lungs is dose-dependent.' Consistent with the existing epidemiologic literatureP'" asthma risk also increased with acetaminophen use duration. Our results are biologically plausible based on pathophysiologic mechanisms describing acetaminophen-induced lung toxicity. The primary organs affected by acetaminophen overdose are the liver and the kidneys. However, acetaminophen also depletes glutathione in the lung tissue, which leads to contraction of the airway smooth muscles by reactive oxygen species, resulting in inflammation and bronchoconstriction.v-" This could lead to symptoms of asthma in individuals who otherwise have subclinical disease." Other mechanisms of acetaminophen-induced lung injury are through the lack of inhibition of the cyclooxygenase enzyme and through increased immunoglobulin E antibody levels as a result of antigenic activity of acetaminophen." To our knowledge, there is a paucity of research on the detailed mechanisms of acetaminophen-induced lung injury, particularly concerning the time of onset of lung injury after acetaminophen consumption in humans. If it is true that acetaminophen first affects the liver and kidneys before affecting the lungs, the process of lung injury might be slower and could require prolonged consumption of acetaminophen. It has been reported that cross-sensitivity to acetaminophen may go un-recognized in aspirin-sensitive asthmatics since the effect of acetaminophen on the lungs is smaller and of slower onset than that of aspirin." Although this finding is in individuals with asthma, it provides some evidence of the slow onset of lung injury with acetaminophen. While an association between chronic acetaminophen consumption and asthma is consistent with other studies and biologically plausible based on the theory of glutathione depletion , further pathophysiological research is warranted to confirm the slower onset of acetaminophen-induced lung toxicity.
Our results should be interpreted in light of exposure misclassification bias. We calculated maximum daily doses based on days' supply and quantity in our dataset and assumed that overlapping prescriptions were consumed concurrently, which could overstate the PMDD in some instances and bias the results toward the null. This is why we refer to "potential" maximum daily doses and average daily doses; however, PMDD was not significantly related to asthma in our study and this calculation does not affect our other acetaminophen dose measures. A larger concern is not accounting for unrecorded OTC acetaminophen use that could bias our results. The acetaminophen product market consists of 48% prescription and 52% OTC products"; thus, we may have accounted for approximately half of all acetaminophen use with our data and our calculated acetaminophen use measures may be understated substantially. If the misclassification is nondifferential (ie, an equal proportion of cases and controls are misclassified), our results would most likely be biased toward the null . If a greaterproportion of cases that exhibited highercomorbidity levels than controls used unrecorded acetaminophen, they could be differentially misclassified as nonexposed and the results would also bias our results toward the null. Although this could be a reason for the lack of an association between recent acetaminophen use and asthma, the same consideration makes our observed association betweenchronicacetaminophen use and asthmamore plausible; perhaps the strength of association was understated. The role of confounding by indication (in this case,reverse causality bias) shouldbeconsidered to explainthe positive association observed in our study." This could arise if a greater proportion of cases than controls used acetaminophen products in the pre-index period to manage early manifestations of asthma.However,93.5% of all acetaminophen prescriptions of cases were opioid/acetaminophencombinationsprimarily used for pain, while cough-cold prescriptions,which would generally be used to treat asthma-like symptoms, accounted for less than 1% of acetaminophen use and cough-cold acetaminophen product use was slightly higher in controls compared to cases.Hence,bias due to reversecausality is unlikely to be of significant concern. Opioid analgesics have beenlinkedto respiratory depression. 32 Since an overwhelming majority of the acetaminophen prescriptions in our sample werefor opioidlac-Prescription-Acquired Acetaminophen Useand the Risk of Asthma in Adults etaminophen combinations, the possibility of opioids contributing to the development of asthma should be considered. Respiratory depression is a greater problem with the use of single-ingredient unmixedopioids comparedto opioid combinations," which is likelydue to a higher narcotic dose in unmixed opioids. A total of 1.9% of the cases and 1.4% of controls used unmixed opioids in the pre-index year and, in spiteof controlling for this,we observeda positive association between chronic acetaminophen use and asthma. The models withoutthis adjustment providedsimilar results. Respiratory depression is kept to a minimum in patients with chronicpain who are maintained on regularly monitored opioid doses," suggesting that respiratory depression may not be a significant concern with regular long-term opioid use. A consensus statement from the American Academy of Pain Medicine and the American Pain Society states that opioid-induced respiratory depression is a short-lived phenomenonand generally occurs in patients who are opioid-naive rather than in those on chronic opioid therapy." This could be because patients develop tolerance to the opioid respiratory depressant effect over time." Therefore, respiratory depression is rare among patients on chronic opioid therapy." This would support the notion that it is acetaminophen and not'the opioids in these combination products that is associated with asthmain our chronicuse models. Given the increased odds of asthma with chronic acetaminophen consumption, clinical decisions guiding acetaminophen use should be basedon a thorough risk-benefit assessment of acetaminophen. A clinicaltrial reported the use of 4 g/day of acetaminophen for 12 months to be safe and effective in 287 patients withosteoarthritis," However, this trial did not measure lung disorders as one of its outcomes and there is no way of knowing whether lung function was affected by acetaminophenuse for a year. Adequately powered clinical trials measuring lung function with chronic acetaminophen use are neededto moreclearly elucidate the asthmarisks of chronic acetaminophen to aid its risk-benefit assessment. Common alternatives to acetaminophen may be NSAIDs and opioid analgesics. However,these are associated with a number of adverse events 41 • 43 and a thorough comparison of risk-benefit profile of acetaminophen and other analgesic alternatives should be used to guide clinical and policy recommendationsaboutacetaminophen use.
Our results should be interpreted in light of some other limitations in addition to exposure misclassification. First, since our data source did not includeclinical measuresto detect asthma, we used ICD-9-CM codes exclusively to define asthma cases. The ICD-9-CM codes for asthma have a low sensitivity and we may not have captured all true cases, which increases the possibility that some controls may indeed have had asthma." Since we selected controls from among the asthma-free individuals at the end of the follow-up period, the ORs calculated in the study represent the odds ratios in the base population and not the risk/rate ratio." Second, in the absence of a well-established definition of chronicity of acetaminophen use, we used a somewhatarbitrarytime windowof 1 year.Third, our study includedonly subjects who were aged 18 years or older. The incidence of asthma is greaterin pediatric patients compared to adults, and if acetaminophenwas the preferred analgesic in individuals with a historyof asthma (since other analgesics like NSAIDs exacerbate asthma) the results could be biased away from the null due to confounding by indication. Finally, sincethis was an insurance database,we did not have data on factors like body mass index,environmental exposure to allergens, and anthropometric measures. Therefore, the possibility of omitted variablebiascannotbe excluded.
Consistent with the results of otherstudies, chronic prescription-acquired acetaminophen use was significantly associated with asthma in a dose-dependent manner,while recent use was not. Based on our study, it does not appear that occasional short-termuse of prescription acetaminophenconfers additional asthma risk,but long-term chronic use should be more carefully considered, particularly in asthma-prone individuals. It wouldbe premature to recommend avoidance of acetaminophen,particularly in those withsymptoms of asthma, because the mostcommon sub-stitute analgesic class,NSAIDs, has been linked to asthma. Epidemiologic studies with morecomplete acetaminophen use measures, including OTC and prescription-acquired use, are warranted to confirmour findings, More basic research to determine the timeof onsetof lunginjury and the causal pathways of asthma associated with acetaminophen use is also needed. 
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MtToDOS: Estudio retrospectivede caso-controlusando una muestra aleatoriade 10% de la reclamacionescomercialesen IMS LifeLinkentre 1997 y 2009. Los casos tenfanque tener por 10 menos una reclamaci6n de incidenciade asma. Se seleccionaronaleatoriamentecontroles a raz6n de 3:1 pareadosde acuerdo a ectad, genero y regi6n.La exposici6n,dosis y duraci6n del uso de APAPse midi6 en el perfodode referenciade 7 a 30 dfas (para uso reciente)y un alio (para uso cr6nico). Para estimar el riesgo de asma asociado con el uso de APAPajuslado por co-morbilidades,uso de otros medicamentosque podrfanaumentar el riesgo de asma y factoresasociadosal sistemade salud, se utiliz6la regresi6nlogisticacondicionada. 
